Bank of America’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-50,000
Closed -$7M 7407
2025
Q3
$7M Buy
50,000
+25,000
+100% +$3.38M ﹤0.01% 3675
2025
Q2
$3.14M Hold
25,000
﹤0.01% 4344
2025
Q1
$3.42M Sell
25,000
-36,700
-59% -$5.25M ﹤0.01% 4190
2024
Q4
$9.44M Buy
61,700
+37,000
+150% +$6.24M ﹤0.01% 2999
2024
Q3
$4.79M Hold
24,700
﹤0.01% 3771
2024
Q2
$5.73M Buy
24,700
+12,200
+98% +$2.65M ﹤0.01% 3500
2024
Q1
$2.7M Sell
12,500
-41,700
-77% -$9.77M ﹤0.01% 4204
2023
Q4
$14M Sell
54,200
-28,200
-34% -$6.93M ﹤0.01% 2505
2023
Q3
$21.2M Buy
82,400
+43,500
+112% +$11.6M ﹤0.01% 1977
2023
Q2
$11.1M Sell
38,900
-44,100
-53% -$13.1M ﹤0.01% 2609
2023
Q1
$23.1M Sell
83,000
-39,800
-32% -$11M ﹤0.01% 1987
2022
Q4
$34M Sell
122,800
-12,300
-9% -$3.47M ﹤0.01% 1590
2022
Q3
$36.1M Sell
135,100
-64,800
-32% -$13.8M ﹤0.01% 1514
2022
Q2
$40.8M Buy
199,900
+74,300
+59% +$15.2M ﹤0.01% 1411
2022
Q1
$26.5M Sell
125,600
-463,100
-79% -$101M ﹤0.01% 1888
2021
Q4
$141M Buy
588,700
+166,900
+40% +$42.9M 0.01% 831
2021
Q3
$119M Buy
421,800
+250,500
+146% +$82.1M 0.01% 872
2021
Q2
$59.3M Buy
171,300
+125,200
+272% +$37.9M 0.01% 1257
2021
Q1
$12.9M Sell
46,100
-2,100
-4% -$566K ﹤0.01% 2474
2020
Q4
$11.8M Buy
48,200
+46,100
+2,195% +$11.9M ﹤0.01% 2352
2020
Q3
$596K Sell
2,100
-11,000
-84% -$3.07M ﹤0.01% 4576
2020
Q2
$3.5M Sell
13,100
-69,100
-84% -$20.8M ﹤0.01% 3169
2020
Q1
$26M Sell
82,200
-208,700
-72% -$63.3M ﹤0.01% 1326
2019
Q4
$86.3M Buy
290,900
+1,900
+0.7% +$527K 0.01% 849
2019
Q3
$67.3M Buy
289,000
+70,100
+32% +$16.3M 0.01% 958
2019
Q2
$51.2M Buy
218,900
+117,800
+117% +$27.2M 0.01% 1112
2019
Q1
$23.9M Sell
101,100
-14,900
-13% -$4.69M ﹤0.01% 1668
2018
Q4
$34.9M Sell
116,000
-81,300
-41% -$25.9M 0.01% 1252
2018
Q3
$69.7M Sell
197,300
-3,800
-2% -$1.31M 0.01% 901
2018
Q2
$58.4M Hold
201,100
0.01% 997
2018
Q1
$55.1M Sell
201,100
-11,800
-6% -$3.66M 0.01% 990
2017
Q4
$67.8M Buy
212,900
+104,200
+96% +$33.4M 0.01% 925
2017
Q3
$34M Buy
108,700
+5,500
+5% +$1.63M 0.01% 1449
2017
Q2
$28M Buy
103,200
+68,000
+193% +$18M 0.01% 1458
2017
Q1
$9.62M Sell
35,200
-323,700
-90% -$91.5M ﹤0.01% 2414
2016
Q4
$102M Sell
358,900
-132,500
-27% -$39.3M 0.02% 660
2016
Q3
$154M Buy
491,400
+115,300
+31% +$34.1M 0.03% 477
2016
Q2
$90.9M Sell
376,100
-125,700
-25% -$33.1M 0.02% 668
2016
Q1
$131M Buy
501,800
+71,500
+17% +$18.9M 0.03% 508
2015
Q4
$132M Sell
430,300
-253,900
-37% -$73M 0.03% 540
2015
Q3
$200M Buy
684,200
+373,900
+120% +$123M 0.05% 391
2015
Q2
$125M Buy
310,300
+111,900
+56% +$44.9M 0.04% 461
2015
Q1
$83.8M Sell
198,400
-86,100
-30% -$33.9M 0.03% 589
2014
Q4
$96.6M Sell
284,500
-17,400
-6% -$5.63M 0.03% 561
2014
Q3
$99.9M Buy
301,900
+45,700
+18% +$15.1M 0.03% 539
2014
Q2
$80.8M Buy
256,200
+162,400
+173% +$48.9M 0.03% 623
2014
Q1
$28.7M Buy
93,800
+6,000
+7% +$1.9M 0.01% 1039
2013
Q4
$24.5M Buy
87,800
+38,500
+78% +$9.96M 0.01% 1195
2013
Q3
$11.9M Buy
49,300
+34,400
+231% +$7.7M ﹤0.01% 1634
2013
Q2
$3.21M Buy
+14,900
New +$3.18M ﹤0.01% 2702

Other funds holding BIIB

Bank of America's BIIB Position: Q1 2026 in Review

Bank of America increased its Biogen (BIIB) stake by 2.4% in Q1 2026, buying an estimated $5.07M and bringing the position to 1,156,369 shares worth $212M. The position accounts for 0.02% of the portfolio, ranked #701.

Bank of America first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $759M in Q3 2017. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Bank of America held 1,156,369 shares of Biogen worth $212M as of Q1 2026.
  • Bank of America bought 27,524 Biogen shares in Q1 2026, an estimated $5.07M.
  • Biogen made up 0.02% of Bank of America's portfolio in Q1 2026, its #701 holding.
  • Bank of America first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Biogen position peaked at $759M in Q3 2017.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.